Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Axitinib treatment turned a man's grey hair back to black.

MK-5108 is safe and shows potential against tumors, especially alone.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

M50054 may help treat hepatitis and hair loss from chemotherapy.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Promising cancer treatments were found, but the manufacturer closed.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.